The natural history of optic neuritis

Reviews in Neurological Diseases

Volumn 3, Issue 2, 2006, Pages 45-56

  Atkins, Edward J ^a   Biousse, Valérie ^b   Newman, Nancy J ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinically isolated syndrome; Multiple sclerosis; Optic neuritis; Optic Neuritis Treatment Trial

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; STEROID;

BLEEDING; COLOR VISION DEFECT; DISEASE COURSE; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PAPILLEDEMA; PERIPAPILLARY HEMORRHAGE; REVIEW; RISK ASSESSMENT; VISUAL ACUITY; VISUAL IMPAIRMENT;

DISEASE PROGRESSION; HUMANS; OPTIC NEURITIS; VISUAL ACUITY;

EID: 33745614063     PISSN: 15452913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Purvin V. Optic neuropathies for the neurologist. Semin Neurol 2000;20:97-110.
2. Frohman E, Frohman T, Zee D, et al. The neuroophthalmology of multiple sclerosis. Lancet Neurol. 2005;4:111-121.
3. Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005; 4:281-288.
4. Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part II: non-conventional MRI, recovery processes, and management. Lancet Neurol. 2005;4:341-348.
5. Korteweg T, Tintoré M, Uidehaag B, et al. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol. 2006;5:221-227.
6. Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol. 2005;139:1101-1108.
7. Ebers GC. Optic neuritis and multiple sclerosis. Arch Neurol. 1985;42:702-704.
8. Kurtzke JF. Optic neuritis or multiple sclerosis. Arch Neurol. 1985;42:704-710.
9. Francis DA, Compston DA, Batchelor JR, McDonald WI. A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up. J Neurol Neurosurg Psychiatry. 1987;50:758-765.
10. Rizzo J, Lessell S. Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long term prospective study. Neurology. 1988; 38:185-190.
11. Miller DH, Ormerod IEC, McDonald WI, et al. The early risk of multiple sclerosis after optic neuritis. J Neurol Neurosurg Psychiatry. 1988; 51:1569-1571.
12. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study. Brain. 1993; 116:135-146.
13. Sandbetg-Wolheim M, Bynke H, Cronqvist S, et al. A long term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol. 1990;27:386-393.
14. Jacobs LD, Kaba SE, Miller CM, et al. Correlation of clinical, MRI and CSF findings in optic neuritis. Ann Neurol. 1997;41:392-398.
15. Söderström M, Jin YP, Hillert J, Link H. Optic neuritis, prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology. 1998; 50:708-714.
16. Ghezzi A, Martinelli V, Torri V, et al. Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol. 1999;246:770-775.
17. Brex P, Ciccarelli O, O'Riordan J, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346:156-164.
18. Jin YP, de Pedro-Cuesta J, Huang YH, Söderström M. Predicting multiple sclerosis at optic neuritis onset. Mult Scler. 2003;9:135-141.
19. Minneboo A, Barkhof F, Polman CH, et al. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol. 2004;61:217-221.
20. Tintoré M, Rovira A, Rio J, et al. Is optic neuritis more benign than other first attacks in multiple sclerosis? Ann Neurol. 2005;57:210-215.
21. Nillson P, Larsson EM, Maly-Sundgren P, et al. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J Neurol. 2005;252:396-402.
22. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992; 326:581-588.
23. Optic Neuritis Study Group. Visual function 5 years after optic neuritis. Arch Ophthalmol. 1997;115:1545-1552.
24. Optic Neuritis Study Group. Visual function more than 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Am J Ophthalmol 2004;137:77-83.
25. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med. 1993;329;1764-1769.
26. Beck RW, Arrington J, Murtagh FR, et al. Brain MRI in acute optic neuritis: experience of the Optic Neuritis Study Group. Arch Neurol. 1993; 8:841-846.
27. Optic Neuritis Study Group. The 5 year risk of MS after optic neuritis: experience of the Optic Neuritis Treatment Trial. Neurology. 1997;49:1404-1413.
28. Optic Neuritis Study Group. Long-term magnetic resonance imaging changes after optic neuritis in patients without clinically definite multiple sclerosis. Arch Neurol. 2004;61:1538-1541.
29. Optic Neuritis Study Group. High risk and low risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 2003;121:944-949.
30. Optic Neuritis Study Group. Neurologic impairment after optic neuritis. Arch Neurol. 2004;61:1386-1389.
31. Jacobs LD, Beck RW, Simon JH, et al. The effect of intramuscular interferon beta 1a treatment initiated at the time of a first acute clinical demyelinating event on the rate of development of clinically definite multiple sclerosis. N Engl J Med. 2000;343:898-904.
32. CHAMPS Study Group. Interferon β-1a for optic neuritis patients at high-risk for multiple sclerosis. Am J Ophthalmol. 2001;132:463-471.
33. Beck RW, Chandler DL, Cole SR, et al. Interferon β-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol. 2002;51:481-490.
34. CHAMPIONS Study Group. IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006;66:678-684.
35. Comi C, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study (ETOMS). Lancet. 2001;357:1576-1582.
36. Sencer W. Suspicion of multiple sclerosis: to tell or not to tell? Arch Neurol. 1988;45:441-442.
37. Frohman E, Racke M. To treat or not to treat? The therapeutic dilemma of idiopathic mono-symptomatic demyelinating syndromes. Arch Neurol. 2000;57:930-932.
38. Rizzo JF, Lessell S. Optic neuritis and ischemic optic neuropathy: overlapping clinical profiles. Arch Ophthalmol. 1991;109:1668-1672.
39. Brasaferri F, Candelise F. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol. 2000;247:435-442.
40. Kaufman DI, Trobe JD, Eggenberger ER, et al. Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Neurology. 2000;54:2039-2044,
41. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology. 1999;52:1479-1484.
42. Tintoré M, Rovira A, Martinez MJ, et al. Isolated demyelinating syndromes: comparison of different magnetic resonance imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol. 2000; 21(4):702-706.
43. McDonald W, Compston A, Edam G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121-127.
44. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald" criteria. Ann Neurol. 2005;58:840-846.
45. Tintoré M, Rovira A, Martinez MJ, et al. Isolated demyelinating syndromes: comparison of different diagnostic MRI criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol. 2000;21:702-706.
46. Dalton CM, Brex PA, Miszkiel KA, et al. New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Ann Neurol. 2003;53:673-676.
47. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain. 1989;112:133-146.
48. Montalban X. The pros and cons of early treatment of relapsing forms of multiple sclerosis. J Neurol. 2004;251(suppl 4):IV/30-IV/34.
49. Dalton CM, Brex PA, Miszkiel KA, et al. Spinal cord MRI in clinically isolated optic neuritis. J Neurol Neurosurg Psychiatry. 2003;74:1577-1580.
50. Frederiksen JL. Can CSF predict the course of optic neuritis? Mult Scler. 1998;4:132-135.
51. Rolak LA, Beck RW, Paty DW, et al. Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial. Neurology. 1996;46:368-372.
52. Cole SR, Beck RW, Moke PS, et al. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group. Neurology. 1998;51:885-887.
53. Masjuan J, Alvarez-Cermeno JC, Garcia-Barragan N, et al. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology. 2006;66:576-578.
54. Achiron A, Kishner I, Sarova-Pinhas I, et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol. 2004;61:1515-1520.
55. Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology. 2005;65:804-810.
56. Revesz T. Axonal lesions in MS: an old story revisited. Brain. 2000;123:203-204.
57. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol. 2001;58:65-70.
58. Filippi M, Tortorella C, Rovaris M, et al. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;68:156-161.